ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Adverse events"

  • Abstract Number: 2320 • 2017 ACR/ARHP Annual Meeting

    Pediatric Rheumatology Infusion Center: Report on Therapeutic Protocols and Infusion Reactions over 4 Years

    Annelle Reed1, Surabhi S. Vinod2, Jamelle Maxwell3, Esraa M. A. Eloseily4,5, Matthew L. Stoll4 and Randy Q. Cron4, 1Pediatric rheumatology, Childrens of Alabama, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Childrens of Alabama, Birmingham, AL, 4Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Pediatrics, Assiut University, Assiut, Egypt

    Background/Purpose: The goals of this report are to describe various therapeutic protocols, volume of intravenous (IV) infusions, and associated adverse events at the University of…
  • Abstract Number: 527 • 2017 ACR/ARHP Annual Meeting

    Cardiovascular Safety of Tocilizumab Versus Abatacept in Patients with Rheumatoid Arthritis: A Multi-Database Study

    Seoyoung C. Kim1, Daniel H. Solomon1, James R. Rogers2, Sara Gale3, Micki Klearman3, Khaled Sarsour3 and Sebastian Schneeweiss2, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Genentech, South San Francisco, CA

    Background/Purpose: While tocilizumab (TCZ) may increase serum lipid levels, recent studies do not suggest an increased cardiovascular (CV) risk associated with TCZ use compared to…
  • Abstract Number: 2599 • 2017 ACR/ARHP Annual Meeting

    Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review

    Gaurav Sharma1, Jasvinder A. Singh2, Mohammed Sohaib Khaleel3 and Shristi Shrestha4, 1Department of Medicine, Division of Immunology and Rheumatology, UAB School of Medicine, Birmingham, AL, 2Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Department of Molecular Cardiology, University of Louisville, Louisville, KY, 4Internal Medicine, Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal

    Background/Purpose: To determine the efficacy and adverse effects of antimalarials in patients with systematic lupus erythematosus (SLE). Methods: A literature search from inception to December…
  • Abstract Number: 543 • 2017 ACR/ARHP Annual Meeting

    Adverse Events in Rheumatoid Arthritis Patients Treated with Disease Modifying Biological Drugs at Hospital Docente Padre Billini in Santo Domingo

    I Mercedes-Núñez, E Tejada-Reyes, Y Cruz-Rojas, E Rodríguez-Bautista, R Munoz-Louis, V Rosario, R Peña-Blanco, T Valdez-Lorie and R Alba-Fériz, Rheumatology, Hospital Docente Padre Billini (HDPB), Santo Domingo, Dominican Republic

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune chronic disease with disability and deforms joints. After the introduction of biological therapies the prognosis of…
  • Abstract Number: 819 • 2017 ACR/ARHP Annual Meeting

    Risks of Non-Cardiovascular Corticosteroid Related Adverse Events and Cancer in Giant Cell Arteritis: A  French Population-Based Cohort Study

    Minh Phuong Do1, Grégory Pugnet2, Guillaume Moulis3, Gregory Guernec4, Maryse Lapeyre-Mestre5 and Laurent Sailler6, 1Faculté de Médecine, Toulouse University, Laboratoire de Pharmacoepidemiologie, Equipe émergente,UMR INSERM 1027, Toulouse, France, 2Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, 3Internal Medicine, Toulouse University Hospital, Toulouse, France, 4Faculté de Médecine, Toulouse University, UMR INSERM 1027, Toulouse, France, 5UMR 1027, INSERM-University of Toulouse, Toulouse, France, 6Medecine Interne, CHU Toulouse, Toulouse, France

    Background/Purpose: Corticosteroid related adverse events are a main concern in patients suffering from giant cell arteritis. Conflicting results are reported on this topic, recurrent events…
  • Abstract Number: 850 • 2017 ACR/ARHP Annual Meeting

    Immune Checkpoint Inhibitors and Inflammatory Myopathies: Data from the US Food and Drug Administration Adverse Event Reporting System

    Xerxes Pundole, Mohsin Shah, Noha Abdel-Wahab and Maria Suarez-Almazor, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX

    Background/Purpose: Immune checkpoint inhibitors have become standard of care for many malignancies. Although these therapies are effective, they can activate the immune system resulting in…
  • Abstract Number: 1182 • 2017 ACR/ARHP Annual Meeting

    Autoantibody Profiling in Prostvac and Ipilimumab Treated Prostate Cancer Patients Reveals Potential Biomarkers of Immune-Related Adverse Events

    Petra Budde1, Jennifer Marte2, Hans-Dieter Zucht1, Saurabh Bhandari1, Manuel Tuschen1, Peter Schulz-Knappe1, James Gulley2, Christopher Heery3, Ravi Madan2 and Jeffrey Schlom2, 1Protagen AG, Dortmund, Germany, 2National Cancer Institute, National Institutes of Health, Bethesda, MD, 3Bavarian Nordic, Inc., Morrisville, NC

    Background/Purpose: Autoantibodies (AAB) targeting self-antigens can be found in two clinically and immunologically opposing diseases, autoimmune diseases and cancer. While in autoimmune diseases, the immune…
  • Abstract Number: 1600 • 2017 ACR/ARHP Annual Meeting

    Lupus Nephritis Is Associated with Increased Rates of Hospitalization for Adverse Events on a Glucocorticoid Toxicity Index and in-Hospital Mortality Compared with Non-Renal Lupus and Matched Controls: An Analysis of Insurance Claims Data

    Katherine Belendiuk1, Huong Trinh2, Matthew Cascino1, Leonard Dragone1, Daniel Keebler1, Jay Garg1 and Paul Brunetta1, 1Genentech, Inc., South San Francisco, CA, 2Genentech, South San Francisco, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) is heterogeneous in its clinical prognosis and lupus nephritis (LN) is a major cause of morbidity and mortality among children…
  • Abstract Number: 1755 • 2017 ACR/ARHP Annual Meeting

    Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis

    Hiromichi Tamaki1, Robert Butler2 and Carol A. Langford3, 1Rheumatology, Cleveland Clinic, Cleveland, OH, 2Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 3Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Low-dose trimethoprim-sulfamethoxazole (LDTS, 160mg-800mg 3x/week or 80mg-400mg/day) is effective for prevention of Pneumocystis jiroveci pneumonia (PCP), a serious opportunistic infection seen in patients with…
  • Abstract Number: 121 • 2017 Pediatric Rheumatology Symposium

    Safety Of Biological Response Modifiers In Childhood Autoimmune Rheumatic Diseases From A Single North Indian Centre

    Sujata Sawhney1, Abhay Shivpuri2 and Manjari Agarwal3, 1Paediatric rheumatology, Senior Consultant, New Delhi, India, 2Division of Pediatric Rheumatology,Institute of Child Health, Post Doctoral Fellow, New Delhi, India, 3Institute of Child Health, Attending Consultant, New Delhi, India

    Background/Purpose: Biologic Response modifiers (BRMs) are sparingly used in India due to: cost & concern of infections. We are a tertiary level centre & have…
  • Abstract Number: 2178 • 2016 ACR/ARHP Annual Meeting

    Statin Use and Increased Risk of Musculoskeletal Conditions: A Retrospective Cohort Study with Propensity Score-Matching

    Una E. Makris1,2, Carlos A. Alvarez2,3,4, Eric M. Mortensen2,4 and Ishak Mansi2,4, 1Rheumatology, UT Southwestern Medical Center, Dallas, TX, 2VA North Texas Health Care System, Dallas, TX, 3Texas Tech University Health Science Center, Dallas, TX, 4UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: Given conflicting evidence regarding statin use and the relationship with musculoskeletal conditions, and the rising disability and societal/personal repercussions associated with both osteoarthritis (OA)…
  • Abstract Number: 2332 • 2016 ACR/ARHP Annual Meeting

    Midterm Outcome of Modular Metal-on-Metal Total Hip Arthroplasty

    Hiroki Wakabayashi1, Masahiro Hasegawa2, Toshio Yamaguchi3, Yohei Naito4 and Akihiro Sudo5, 1Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Japan, 2Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, 3Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan, 4Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Mie, Japan, 5Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan

    Background/Purpose:  Wear, osteolysis, and late aseptic loosening associated with ultrahigh-molecular-weight polyethylene components used in total hip arthroplasties (THA) have led to increased interest in metal-on-metal…
  • Abstract Number: 2444 • 2016 ACR/ARHP Annual Meeting

    Effects of Disease Activity and Drug Exposure on Pregnancy Outcomes with Inflammatory Arthritis

    Emily Fishman1, Kathryn H. Dao2 and John J. Cush3, 1Texas A&M HSC College of Medicine, Dallas, TX, 2Texas Health, Dallas, TX, 3Baylor Research Institute, Dallas, TX

    Background/Purpose: Pregnancy is often encountered in women who have inflammatory arthritis (IA), such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile arthritis (JIA) or ankylosing…
  • Abstract Number: 2547 • 2016 ACR/ARHP Annual Meeting

    Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis

    Frank Buttgereit1, Jonna Amann2, Friederike Breitenfeldt3, Dörte Huscher4, Johannes WJ Bijlsma5 and Johannes WG Jacobs6, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 3Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, 4Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, 5ARC, Amsterdam, Netherlands, 6Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Glucocorticoids (GCs) are frequently and often chronically used for the treatment of rheumatoid arthritis (RA) and other immune diseases and vasculitis. An estimated 0.8–1.2%…
  • Abstract Number: 2595 • 2016 ACR/ARHP Annual Meeting

    Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry

    Arthur F. Kavanaugh1, Jamie Geier2, Clifton Bingham III3, Connie Chen2, George W. Reed4,5, Katherine C. Saunders4, Yan Chen6, Andrew Koenig6, Laura Cappelli7, Jeffrey D. Greenberg4,8 and Joel M. Kremer9, 1University of California, San Diego School of Medicine, LaJolla, CA, 2Pfizer, Inc., New York, NY, 3Johns Hopkins University, Baltimore, MD, 4Corrona, LLC, Southborough, MA, 5University of Massachusetts Medical School, Worcester, MA, 6Pfizer, Inc., Collegeville, PA, 7Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, 8NYU School of Medicine, New York, NY, 9Albany Medical College and the Center for Rheumatology, Albany, NY

    Background/Purpose: An interim analysis of a prospective observational 3+ year study, embedded within the US Corrona Rheumatoid Arthritis (RA) registry (14 years and ongoing), was…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology